In a phase 1 study using trametinib in advanced melanomas, trametinib did not demonstrate efficacy in the majority of patients with BRAF/NRAS wild-types, but one patient with an NF1 mutation had a stable disease [119]. The gene discussed is NF1; the disease is melanoma.